Stock Ratings / Health Care / CYPH / earnings

TTRX (38) ARCT (25) AVIR (33) ENTA (20) ⌘ Pro Terminal →

Cypherpunk Technologies Inc. (CYPH) Next Earnings Date & Expected ±12.5% Move

$2.98 -9.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.92

Cypherpunk Technologies Inc. (CYPH) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $321.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CYPH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CYPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cypherpunk Technologies Inc. (NASDAQ: CYPH) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.98 (-9.97% 1D, market cap $321.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CYPH ranks #426 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CYPH compare to TTRX and ARCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYPH carries a Roarable D- (42/100 RQD), trailing P/E of 71.3x, gross margin of —, and ROIC of -23.3%. By comparison, TTRX (Turn Therapeutics Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -28.3%, cap $318.5M) and ARCT (Arcturus Therapeutics Holdings Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $313.5M). Among the 5-stock peer group, CYPH leads on earnings multiple (71.3x) while CYPH leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CYPH?

▼

Per CYPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001509745), Cypherpunk Technologies Inc. generated $0 in revenue, $5.0M in net income, and -$43.9M in free cash flow against $163.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.92 (-1.98%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYPH)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY CYPH SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 50.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.84-1.1% Next Q

Q2 (-2Q)

Grade E$2.81+11.4% Next Q

Q3 (-1Q)

Grade E$3.13-4.8% Next Q

Current

Grade D-$2.98-7% Hist 90D α

Trajectory: E (34) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CYPH Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CYPH currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.81) and Max Pain ($3.13) forces dealer call-delta covering toward $4.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYPH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CYPH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.37 Expected Swing

MODEL EARNINGS SETUP GAUGE

CYPH Quantitative Pre-Earnings Setup: 42/100

Trailing EPS: $0.05 • YoY Revenue Growth: 12.4%

Model Bullish Setup (42/100)Model Risk Weight (58/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$5.0M	-$43.9M	52%
FY 2024	2024-12-31	$0	-$68.0M	-$60.3M	52%
FY 2023	2023-12-31	$0	-$81.0M	-$43.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYPH)

✓Walkthrough of CYPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CYPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +204.08%▲ ASCENDING CHANNEL

2026-11-03O $3.31H $3.31L $2.98C $2.98VOL 14.41M

RES: $4.99SUP: $0.77SMA50: $2.81SMA200: $1.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CYPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CYPH Butterfly Map → + Track CYPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

46.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CYPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CYPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CYPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYPH)

Health Care Rank #426 of 1016 ⚔️ TTRX vs CYPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CYPH vs. TTRX, ARCT, AVIR, ENTA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cypherpunk Technologies Inc. (CYPH) ranks #426 by composite RQD confidence (42/100, grade D-) and #508 by equity capitalization ($321.1M). Within this direct 5-issuer industry benchmark cohort, CYPH leads on earnings valuation at 71.3x trailing P/E, while CYPH leads on capital efficiency and profitability with -23.3% ROIC and — gross margin. CYPH currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CYPH ACTIVE Cypherpunk Technologies Inc.	D-	42/100	71.3x	—	-23.3%	-9.97%	$321.1M	Benchmark Subject
TTRX Turn Therapeutics Inc.	D-	38/100	—	—	-28.3%	-2.70%	$318.5M	/ttrx-vs-cyph →
ARCT Arcturus Therapeutics Holdings Inc.	E	25/100	—	—	-35.0%	-9.22%	$313.5M	/arct-vs-cyph →
AVIR Atea Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-4.64%	$329.6M	/avir-vs-cyph →
ENTA Enanta Pharmaceuticals Inc.	E	20/100	—	—	-35.0%	-3.95%	$311.9M	/enta-vs-cyph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001509745

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cypherpunk Technologies Inc. (CYPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $5.0M, operating cash flow of -$43.9M, and free cash flow of -$43.9M (+27.2% YoY). On the balance sheet, CYPH closed FY2025 with $163.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$5.0M	-$43.9M	-$43.9M	$163.2M	—
FY2024 (FY)	2024-12-31	$0	-$68.0M	-$60.3M	-$60.3M	$49.1M	—
FY2023 (FY)	2023-12-31	$0	-$81.0M	-$43.8M	-$43.8M	—	—

3. CYPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CYPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CYPH compare to TTRX and ARCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CYPH?

Where is CYPH trading relative to its 50-day, 200-day, and 52-week technical levels?

CYPH last traded at $2.98 (-9.97% on volume of 14,408,158 shares), positioning the stock +6.05% above its 50-day simple moving average ($2.81) and +129.23% above its 200-day simple moving average ($1.30). Across its 52-week range of $0.39 to $4.19, CYPH sits at the 68.2% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.61 to $3.35).

CYPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CYPH's next earnings date?

Based on SEC filing cadence, Cypherpunk Technologies Inc. (CYPH)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CYPH stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for CYPH, spanning a range between $2.61 and $3.35.

Direct Sub-Reports: CYPH RQD Cockpit CYPH 12M Forecast CYPH Earnings & Move CYPH Dividends & DRIP CYPH Insiders & 13F CYPH Whale Options CYPH Profit Sankey CYPH News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CYPH — Cypherpunk Technologies Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CYPH scores 45 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, ROIC is -23.3% and FCF yield is -12.31%. This is the weakest pillar and signals that the business is currently consuming capital rather than generating it. For a prospective investor, the upside case here depends on a future shift to positive cash generation, which the source data does not show in reported periods.
Whale 13F Flow: 17 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. This is the strongest pillar and suggests institutional interest, which can support liquidity and price momentum. However, institutional positioning does not offset weak fundamentals and may reflect short-horizon trading.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider flow does not provide a conviction signal supporting the stock.
Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity. The stock moves in line with the broad market, offering no defensive cushion or macro-specific tailwind.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These figures sit in a middling-to-weak range, indicating limited financial strength with no clear balance-sheet advantage.

Taken together, the pillars show a stock with heavy institutional interest but weak cash generation, low insider conviction, and a modest balance sheet. The valuation tradeoff is significant: per the market data, P/E (TTM) is 71.3 against EPS (TTM) of 0.05, so the price is high relative to reported earnings. Upside would require sustained improvement in cash flow; the current evidence does not demonstrate this.

Business

Cypherpunk Technologies Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, it has a market capitalization of $0.4B. Per the SEC financials, reported revenue is $0.0M in each listed period. Not available in source data: products sold, customer base, and revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-41.1M	$5.0M	N/A	$-43.9M	$14.0M	N/A
FY 2024	$0.0M	$-70.1M	$-68.0M	N/A	$-60.3M	$47.2M	N/A
FY 2023	$0.0M	$-87.0M	$-81.0M	N/A	$-43.8M	N/A	N/A

Per the market data, gross, operating, and net margins are each 0%, and ROIC is -23.3%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Reported operating income was negative in all three periods, and FCF was negative in all three. Cash fell from $47.2M in FY 2024 to $14.0M in FY 2025 per the SEC financials. Net income in FY 2025 was positive at $5.0M despite a negative operating income of $-41.1M; the source does not explain this gap.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six items reference CYPH, all tagged as MARKET WIRE with a YELLOW light:

A Moomoo report on revenue breakdown and composition.
A debelegger.nl stock price and chart analysis.
A kalkine.ca headline noting a 16% decline in a single day.
A Bybit price-prediction report for 2026 to 2031.
A Stock Titan report stating that Winklevoss Treasury Investments exercised CYPH warrants at $0.001 per share.
A Timothy Sykes report describing a volatility base.

Risk watch items: the reported 16% single-day decline, and the warrant exercise, which is a potential dilution source. Per the Butterfly Supply-Chain Graph, the supply-chain value is NONE and there are no proprietary signals.

Open Questions

What drives the FY 2025 positive net income of $5.0M when operating income was $-41.1M, and is it recurring?
What is the revenue source, given reported revenue of $0.0M in every period?
What does the warrant exercise at $0.001 per share imply for share count and dilution?
What is the FY 2025 debt balance, which the source lists as N/A?
What is the path to positive free cash flow, given FCF was negative in all three reported periods?

CYPH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cypherpunk Technologies Inc. (CYPH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CYPH Debate Forum (3) ↓

🟡 MARKET WIRE Moomoo • 18h ago

Cypherpunk Technologies (CYPH) Revenue Breakdown - Main Composition

Moomoo report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.debelegger.nl • 21h ago

Cypherpunk Technologies (CYPH) Stock Price, Chart & Analysis

www.debelegger.nl report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

What Cypherpunk Technologies (NASDAQ:CYPH) Penny Stock Holders Should Weigh After a 16% Decline Today

kalkine.ca report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Bybit • 1d ago

Cypherpunk Technologies (Dinari Tokenized Stock) (CYPH) Price Prediction for 2026 to 2031

Bybit report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Winklevoss Treasury Investments exercises Cypherpunk (CYPH) warrants at $0.001 per share.

Stock Titan report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 1d ago

CYPH Stock Holds Key Level As Traders Watch Volatility Base

Timothy Sykes report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 1d ago

CYPH Stock Holds Support As Traders Study Volatile Chart

StocksToTrade report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Cypherpunk Technologies Inc. (NASDAQ: CYPH) Share Price, CYPH Stock News, CYPH Share Price & Updates

kalkine.ca report covering Cypherpunk Technologies Inc. (CYPH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CYPH Bull vs. Bear Conversation Board — What's Your Call at $2.98?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CYPH 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.91 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CYPH (D • RQD 45/100) a Buy at $3.31?

Welcome to the CYPH (Cypherpunk Technologies Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (71.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.68 (-19.0%)

Spot @ $3.31

Pump the brakes on CYPH — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CYPH, but look at what you are paying: 71.3x trailing P/E with tightening sector spreads. Unless Cypherpunk Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.87 (+16.9%)

Spot @ $3.31

CYPH cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CYPH, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.31 (52-wk range $0.39 - $4.19), any beat on forward guidance forces shorts and underweight funds to chase.